Histone Deacetylases Inhibitors in the Treatment of Retinal Degenerative Diseases: Overview and Perspectives
Retinal degenerative diseases are one of the important refractory ophthalmic diseases, featured with apoptosis of photoreceptor cells. Histone acetylation and deacetylation can regulate chromosome assembly, gene transcription, and posttranslational modification, which are regulated by histone acetyl...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2015/250812 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551605181874176 |
|---|---|
| author | Hua Zhang Xufeng Dai Yan Qi Ying He Wei Du Ji-jing Pang |
| author_facet | Hua Zhang Xufeng Dai Yan Qi Ying He Wei Du Ji-jing Pang |
| author_sort | Hua Zhang |
| collection | DOAJ |
| description | Retinal degenerative diseases are one of the important refractory ophthalmic diseases, featured with apoptosis of photoreceptor cells. Histone acetylation and deacetylation can regulate chromosome assembly, gene transcription, and posttranslational modification, which are regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs), respectively. The histone deacetylase inhibitors (HDACis) have the ability to cause hyperacetylation of histone and nonhistone proteins, resulting in a variety of effects on cell proliferation, differentiation, anti-inflammation, and anti-apoptosis. Several HDACis have been approved for clinical trials to treat cancer. Studies have shown that HDACis have neuroprotective effects in nervous system damage. In this paper, we will summarize the neuroprotective effects of common HDACis in retinal degenerative diseases and make a prospect to the applications of HDACis in the treatment of retinal degenerative diseases in the future. |
| format | Article |
| id | doaj-art-49069e6f356c4f2fa91443239a23648d |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-49069e6f356c4f2fa91443239a23648d2025-02-03T06:00:57ZengWileyJournal of Ophthalmology2090-004X2090-00582015-01-01201510.1155/2015/250812250812Histone Deacetylases Inhibitors in the Treatment of Retinal Degenerative Diseases: Overview and PerspectivesHua Zhang0Xufeng Dai1Yan Qi2Ying He3Wei Du4Ji-jing Pang5Eye Hospital, School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang 325027, ChinaEye Hospital, School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang 325027, ChinaEye Hospital, School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang 325027, ChinaEye Hospital, School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang 325027, ChinaDepartment of Ophthalmology, University of Florida, Gainesville, FL, USAEye Hospital, School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang 325027, ChinaRetinal degenerative diseases are one of the important refractory ophthalmic diseases, featured with apoptosis of photoreceptor cells. Histone acetylation and deacetylation can regulate chromosome assembly, gene transcription, and posttranslational modification, which are regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs), respectively. The histone deacetylase inhibitors (HDACis) have the ability to cause hyperacetylation of histone and nonhistone proteins, resulting in a variety of effects on cell proliferation, differentiation, anti-inflammation, and anti-apoptosis. Several HDACis have been approved for clinical trials to treat cancer. Studies have shown that HDACis have neuroprotective effects in nervous system damage. In this paper, we will summarize the neuroprotective effects of common HDACis in retinal degenerative diseases and make a prospect to the applications of HDACis in the treatment of retinal degenerative diseases in the future.http://dx.doi.org/10.1155/2015/250812 |
| spellingShingle | Hua Zhang Xufeng Dai Yan Qi Ying He Wei Du Ji-jing Pang Histone Deacetylases Inhibitors in the Treatment of Retinal Degenerative Diseases: Overview and Perspectives Journal of Ophthalmology |
| title | Histone Deacetylases Inhibitors in the Treatment of Retinal Degenerative Diseases: Overview and Perspectives |
| title_full | Histone Deacetylases Inhibitors in the Treatment of Retinal Degenerative Diseases: Overview and Perspectives |
| title_fullStr | Histone Deacetylases Inhibitors in the Treatment of Retinal Degenerative Diseases: Overview and Perspectives |
| title_full_unstemmed | Histone Deacetylases Inhibitors in the Treatment of Retinal Degenerative Diseases: Overview and Perspectives |
| title_short | Histone Deacetylases Inhibitors in the Treatment of Retinal Degenerative Diseases: Overview and Perspectives |
| title_sort | histone deacetylases inhibitors in the treatment of retinal degenerative diseases overview and perspectives |
| url | http://dx.doi.org/10.1155/2015/250812 |
| work_keys_str_mv | AT huazhang histonedeacetylasesinhibitorsinthetreatmentofretinaldegenerativediseasesoverviewandperspectives AT xufengdai histonedeacetylasesinhibitorsinthetreatmentofretinaldegenerativediseasesoverviewandperspectives AT yanqi histonedeacetylasesinhibitorsinthetreatmentofretinaldegenerativediseasesoverviewandperspectives AT yinghe histonedeacetylasesinhibitorsinthetreatmentofretinaldegenerativediseasesoverviewandperspectives AT weidu histonedeacetylasesinhibitorsinthetreatmentofretinaldegenerativediseasesoverviewandperspectives AT jijingpang histonedeacetylasesinhibitorsinthetreatmentofretinaldegenerativediseasesoverviewandperspectives |